+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4774900
  • Report
  • May 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • AstraZeneca plc
  • Baxter International Inc.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann La-Roche Ltd
  • GlaxoSmithKline PLC
  • MORE
Certain factors that are driving the market growth include a rise in prevalence of NHL, demand for innovative drugs and novel technologies, and an increase in the number of FDA approvals for NHL therapy drugs.
  • In addition, the increase in public awareness about NHL, robust drug pipeline for the treatment of the disease, improved diagnostic techniques to detect NHL, and the increase in the prevalence of non-Hodgkin lymphoma are the factors fuelling the NHL therapeutics market across the world.
  • However, the high cost of NHL drugs and various complications associated with them are acting as major restraints for the non-Hodgkin lymphoma therapeutics market. Additionally, stringent regulatory guidelines are also limiting the growth of the market.
Key Market Trends

The Radiation Therapy Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Radiotherapy is the use of high-energy beams or particles to kill cancer cells, and can be delivered from a source outside the body, i.e. external beam radiation or internally, such as brachytherapy. Usually, radiation treatments are given five days per week for several weeks. Radiation therapy is most effective, when this kind of lymphoma is only found in one part of the body. According to the American Cancer Society, Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States that accounts for about 4% of all cancers. For non-Hodgkin disease, radiation therapy is used in the early stages of the diseases. In the case of advanced lymphomas, radiation therapy is used along with chemotherapy for better treatment of Non-Hodgkin Lymphoma. If the lymphoma is widespread, palliative radiotherapy is very helpful. Radiotherapy is often very good at destroying non-Hodgkin disease cells. It mainly helps in relieving the symptoms caused by the lymphomas.

Asia-Pacific is Expected to Show the Highest Growth Rate Over the Forecast Period

By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America. North America dominates the non-Hodgkin lymphoma therapeutics market, due to increasing technological advancements and the rising incidences of NHL in the country. However, Asia-Pacific is also expected to propel the non-Hodgkin lymphoma therapeutics market, owing to factors, such as increasing accessibility to healthcare facilities in the region and increasing prevalence of NHL. According to the research article published in 2018, it was estimated that the incidence rate of non-Hodgkin lymphoma was 7.11 per 100,000 per year in China. As the incidence and prevalence of non-Hodgkin lymphoma are increasing year-on-year, many manufacturing companies are investing to develop novel drug therapies to meet the growing demand of therapeutics. Hence, with the growing awareness of the disease, increasing government initiatives, and an increase in the burden of disease, the market is expected to grow over the forecast period.

Competitive Landscape

The non-Hodgkin lymphoma therapeutics market is highly competitive and consists of a few major players. Companies, like AstraZeneca, Baxter International Inc, Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, etc. hold the substantial market share in the non-Hodgkin lymphoma therapeutics market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4


  • AstraZeneca plc
  • Baxter International Inc.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann La-Roche Ltd
  • GlaxoSmithKline PLC
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Non-Hodgkin Lymphoma (NHL)
4.2.2 Demand for Innovative Drugs and Novel Technologies
4.3 Market Restraints
4.3.1 High Cost of the Drugs Used in NHL Therapy
4.3.2 Side Effects Associated with NHL Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type of Therapy
5.1.1 Chemotherapy
5.1.2 Radiation Therapy
5.1.3 Targeted Therapy
5.1.4 Other Types of Therapies
5.2 By Cell Type
5.2.1 B-Cell Lymphomas
5.2.2 T-Cell Lymphoma
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East & Africa GCC South Africa Rest of Middle-East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AstraZeneca plc
6.1.2 Baxter International Inc.
6.1.3 Bayer AG
6.1.4 Bristol Myers Squibb Company
6.1.5 Eli Lilly and Company
6.1.6 F. Hoffmann La-Roche Ltd
6.1.7 GlaxoSmithKline PLC
6.1.8 Seattle Genetics
6.1.9 Teva Pharmaceuticals

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • AstraZeneca plc
  • Baxter International Inc.
  • Bayer AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann La-Roche Ltd
  • GlaxoSmithKline PLC
  • Seattle Genetics
  • Teva Pharmaceuticals
Note: Product cover images may vary from those shown